New consortium argues longevity medicine starts before birth

A new international collaboration, the Life-course Healthy Longevity Consortium, has called for a fundamental reassessment of how the longevity sector defines its patients. In a correspondence published in Nature Health, researchers from geroscience, pediatrics and obstetrics argue that healthy aging is a continuous process spanning the entire life course, rather than a condition to be treated only in later years.

Until now, the longevity medicine industry has poured resources into measuring and reversing biological aging in adults. The consortium warns this approach ignores decades of evidence showing that maternal health, the intrauterine environment and early childhood permanently shape physiological resilience and chronic disease susceptibility. The authors note that current healthy longevity medicine has “primarily focused on adult populations” despite clear evidence that early biological and environmental exposures dictate long-term health.

This shift carries significant implications for the diagnostics market. The tools currently favoured by the industry, such as epigenetic clocks, were built using adult data to measure accumulated molecular damage. The consortium warns these existing biomarkers “cannot be directly extrapolated to children without risking misinterpretation.” In childhood, an advanced biological age could simply indicate healthy maturation rather than pathology.

“Healthy development and biological aging are distinct processes,” said Professor Evelyne Bischof. “The Life-course Healthy Longevity Consortium therefore integrates developmental, functional, molecular, environmental and clinical biomarkers rather than relying on adult epigenetic clocks alone. Our goal is to identify trajectories that reflect optimal development versus early biological vulnerability across the life course.”

Professor Tzipora Strauss said the consortium’s central premise is that “healthy longevity begins long before aging itself, through the biological and environmental processes that shape development from preconception onward.” She argued that optimizing early development matters because “the trajectory of aging is shaped long before aging itself becomes clinically apparent.”

Rather than starting new studies, the consortium is focusing on research infrastructure. It plans to harmonize existing pregnancy, birth and pediatric cohorts to track individuals from preconception through adulthood. “Rather than duplicating efforts, we aim to connect and harmonize these invaluable resources, because together we are stronger,” Bischof said.

For European healthcare systems and life sciences investors, this represents a potential pivot point. If the consortium’s framework gains traction, research and development investment may gradually shift away from late-life interventions toward pediatric diagnostics and early-life preventive tools, altering the commercial landscape of longevity science.